C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD.
暂无分享,去创建一个
Jun Lu | Yong-Jian Wang | Jun Lu | Yuanlin Zheng | Feng-Juan Yan | Xu Wang | Song-En Wang | Hai-Ting Hong | Qin Ye | Yuan-Lin Zheng | Yong-Jian Wang | Qin Ye | Feng-Juan Yan | Song-En Wang | Xu Wang | Hai-Ting Hong
[1] E. Wagner,et al. AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.
[2] Alexis M. Kalergis,et al. Innate Immunity and Inflammation in NAFLD/NASH , 2016, Digestive Diseases and Sciences.
[3] B. Neuschwander‐Tetri,et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.
[4] Richard A. Flavell,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.
[5] G. Targher,et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.
[6] W. Li,et al. Novel function of the chromosome 7 open reading frame 41 gene to promote leukemic megakaryocyte differentiation by modulating TPA-induced signaling , 2014, Blood Cancer Journal.
[7] Gianluca Svegliati-Baroni,et al. Lipotoxicity and the gut-liver axis in NASH pathogenesis. , 2018, Journal of hepatology.
[8] Julia C. Engelmann,et al. Increased expression of c-Jun in nonalcoholic fatty liver disease , 2013, Laboratory Investigation.
[9] M. Abraham,et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.
[10] A. Sanyal,et al. Lipotoxicity in NASH. , 2012, Journal of hepatology.
[11] T. Kerppola,et al. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity , 2001, Oncogene.
[12] E. Wagner,et al. Promoter Specificity and Biological Activity of Tethered AP-1 Dimers , 2002, Molecular and Cellular Biology.
[13] H. Tilg,et al. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.
[14] Keith G. Tolman,et al. Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease , 2007 .
[15] G. Marchesini,et al. NASH: From liver diseases to metabolic disorders and back to clinical hepatology , 2002, Hepatology.
[16] Y. Koyama,et al. Liver inflammation and fibrosis. , 2017, The Journal of clinical investigation.
[17] W. Wahli,et al. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .
[18] H. Tilg,et al. Insulin resistance, inflammation, and non-alcoholic fatty liver disease , 2008, Trends in Endocrinology & Metabolism.
[19] Q. Anstee,et al. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. , 2016, Annual review of pathology.
[20] A. Zou,et al. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells , 2016, BioMed research international.
[21] Zhi‐Gang She,et al. Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver , 2018, Hepatology.
[22] H. Blum,et al. The transcription factor c‐Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival , 2012, Hepatology.
[23] L. Henry,et al. NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .
[24] Guido Gerken,et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.
[25] Hongliang Li,et al. Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator‐Activated Receptor γ in Mice , 2019, Hepatology.
[26] E. Brunt,et al. Nonalcoholic fatty liver disease: pathology and pathogenesis. , 2010, Annual review of pathology.
[27] T. Lawrence. The nuclear factor NF-kappaB pathway in inflammation. , 2009, Cold Spring Harbor perspectives in biology.
[28] A. Schmitt-Graeff,et al. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression , 2019, Cell Death & Differentiation.
[29] Yong-Jian Wang,et al. ZNF300 stimulates fatty acid oxidation and alleviates hepatosteatosis through regulating PPARα. , 2019, The Biochemical journal.
[30] J. Olefsky,et al. Insulin sensitivity: modulation by nutrients and inflammation. , 2008, The Journal of clinical investigation.
[31] S. Shoelson,et al. Inflammation and the IKKβ/IκB/NF-κB axis in obesity- and diet-induced insulin resistance , 2003, International Journal of Obesity.
[32] G. Tarantino,et al. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. , 2011, World journal of gastroenterology.
[33] A. Gentilini,et al. Molecular Pathogenesis of NASH , 2016, International journal of molecular sciences.
[34] Hongliang Li,et al. The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis , 2016, Hepatology.
[35] Z. Ronai. JNKing Revealed. , 2004, Molecular cell.
[36] F. Bessone,et al. Molecular pathways of nonalcoholic fatty liver disease development and progression , 2018, Cellular and Molecular Life Sciences.
[37] S. Kaneko,et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. , 2007, Gastroenterology.
[38] F. Gonzalez,et al. Hepatic PPARγ and LXRα independently regulate lipid accumulation in the livers of genetically obese mice , 2014, FEBS letters.
[39] S. Akira,et al. c‐Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide–dependent impairment of oxidative DNA repair , 2010, Hepatology.
[40] D. Kardassis,et al. A Dominant Negative Form of the Transcription Factor c-Jun Affects Genes That Have Opposing Effects on Lipid Homeostasis in Mice* , 2007, Journal of Biological Chemistry.
[41] Y. Lyou,et al. Maturin is a novel protein required for differentiation during primary neurogenesis. , 2013, Developmental biology.
[42] Zan Huang,et al. ZNF300 tight self-regulation and functioning through DNA methylation and histone acetylation , 2017, Cell & Bioscience.
[43] Hongliang Li,et al. Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator‐Activated Receptor γ in Mice , 2019, Hepatology.
[44] Yujie Ren,et al. Induction of INKIT by Viral Infection Negatively Regulates Antiviral Responses through Inhibiting Phosphorylation of p65 and IRF3. , 2017, Cell host & microbe.
[45] E. Latz,et al. Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.
[46] C. Byrne,et al. NAFLD: a multisystem disease. , 2015, Journal of hepatology.